VICTOR J. MARDER, M.D.
This content is PDF only. Please click on the PDF icon to access.
The development and acceptance of new pharmacologic approaches to treatment are often painstakingly slow. Consider heparin: This drug is the standard anti-thrombotic agent for treating acute venous thrombosis and pulmonary embolism, but it took more than 20 years from the time of its discovery in 1916 (1) until its first clinical use for thrombosis (2). It was another 20 years before heparin was a popular alternative to surgical venous interruption as a means of preventing pulmonary embolism. Now consider thrombolytic agents: Streptokinase was not described until 1933 (3), urokinase until 1951 (4), and neither agent was administered therapeutically for thrombotic
MARDER VJ. Are We Using Fibrinolytic Agents Often Enough?. Ann Intern Med. ;93:136–137. doi: 10.7326/0003-4819-93-1-136
Download citation file:
Published: Ann Intern Med. 1980;93(1_Part_1):136-137.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use